Hypertension. 2005;46:937-942
Published online before print September 12, 2005,
doi: 10.1161/01.HYP.0000175813.04375.8a
(Hypertension. 2005;46:937.)
© 2005 American Heart Association, Inc.
Evidence for a Functional Interaction of the Angiotensin-(17) Receptor Mas With AT1 and AT2 Receptors in the Mouse Heart
Carlos Henrique de Castro;
Robson Augusto Souza dos Santos;
Anderson José Ferreira;
Michael Bader;
Natalia Alenina;
Alvair Pinto de Almeida
From the Departments of Physiology and Biophysics (C.H.C., R.A.S.d.S., A.P.d.A.) and Morphology (A.J.F.), Federal University of Minas Gerais, Belo Horizonte, Brazil, and the Max Delbrück Center for Molecular Medicine (M.B., N.A.), Berlin-Buch, Germany.
Correspondence to Alvair Pinto de Almeida, PhD, Departamento de Fisiologia e Biofísica, Av Antônio Carlos 6627, IC-UFMG 31 270-901, Belo Horizonte, MG, Brazil. E-mail apa{at}icb.ufmg.br
The aim of this study was to evaluate the angiotensin (Ang)-(17) effects in isolated mouse hearts. The hearts of male C57BL/6J and knockout mice for the Ang-(17) receptor Mas were perfused by the Langendorff method. After a basal period, the hearts were perfused for 20 minutes with Krebs-Ringer solution (KRS) alone (control) or KRS containing Ang-(17) (0.22 pmol/L), the Mas antagonist A-779 (115 nmol/L), the angiotensin type 1 receptor antagonist losartan (2.2 µmol/L), or the angiotensin type 2 receptor antagonist PD123319 (130 nmol/L). To evaluate the involvement of Ang receptors, prostaglandins, and nitric oxide in the Ang-(17) effects, the hearts were perfused for 20 to 30 minutes with KRS containing either A-779, losartan, PD123319, indomethacin, or NG-nitro-L-arginine methyl ester (L-NAME) alone or in association with subsequent Ang-(17) perfusion. In addition, hearts from Mas-knockout mice were perfused for 20 minutes with KRS containing Ang-(17) (0.22 pmol/L) and losartan. Ang-(17) alone did not change the perfusion pressure. Strikingly, in the presence of losartan, 0.22 pmol/L Ang-(17) induced a significant decrease in perfusion pressure, which was blocked by A-779, indomethacin, and L-NAME. Furthermore, this effect was not observed in Mas-knockout mice. In contrast, in the presence of PD123319, Ang-(17) produced a significant increase in perfusion pressure. This change was not modified by the addition of A-779. Losartan reduced but did not abolish this effect. Our results suggest that Ang-(17) produces complex vascular effects in isolated, perfused mouse hearts involving interaction of its receptor with angiotensin type 1- and type 2-related mechanisms, leading to the release of prostaglandins and nitric oxide.
Key Words: receptors, angiotensin cardiac function heart angiotensin antagonist prostaglandins
This article has been cited by other articles:

|
 |

|
 |
 
J. Zimpelmann and K. D. Burns
Angiotensin-(1-7) activates growth-stimulatory pathways in human mesangial cells
Am J Physiol Renal Physiol,
February 1, 2009;
296(2):
F337 - F346.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Rentzsch, M. Todiras, R. Iliescu, E. Popova, L. A. Campos, M. L. Oliveira, O. C. Baltatu, R. A. Santos, and M. Bader
Transgenic Angiotensin-Converting Enzyme 2 Overexpression in Vessels of SHRSP Rats Reduces Blood Pressure and Improves Endothelial Function
Hypertension,
November 1, 2008;
52(5):
967 - 973.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Xu, A. C. Costa-Goncalves, M. Todiras, L. A. Rabelo, W. O. Sampaio, M. M. Moura, S. Sousa Santos, F. C. Luft, M. Bader, V. Gross, et al.
Endothelial Dysfunction and Elevated Blood Pressure in Mas Gene-Deleted Mice
Hypertension,
February 1, 2008;
51(2):
574 - 580.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. O. Sampaio, C. Henrique de Castro, R. A.S. Santos, E. L. Schiffrin, and R. M. Touyz
Angiotensin-(1-7) Counterregulates Angiotensin II Signaling in Human Endothelial Cells
Hypertension,
December 1, 2007;
50(6):
1093 - 1098.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. K. Becker, G. M. Etelvino, T. Walther, R. A. S. Santos, and M. J. Campagnole-Santos
Immunofluorescence localization of the receptor Mas in cardiovascular-related areas of the rat brain
Am J Physiol Heart Circ Physiol,
September 1, 2007;
293(3):
H1416 - H1424.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. C De Mello, C. M Ferrario, and J. A Jessup
Beneficial versus harmful effects of Angiotensin (1-7) on impulse propagation and cardiac arrhythmias in the failing heart
Journal of Renin-Angiotensin-Aldosterone System,
June 1, 2007;
8(2):
74 - 80.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Toda, K. Ayajiki, and T. Okamura
Interaction of Endothelial Nitric Oxide and Angiotensin in the Circulation
Pharmacol. Rev.,
March 1, 2007;
59(1):
54 - 87.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Keidar, M. Kaplan, and A. Gamliel-Lazarovich
ACE2 of the heart: From angiotensin I to angiotensin (1-7)
Cardiovasc Res,
February 1, 2007;
73(3):
463 - 469.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. O. Sampaio, R. A. Souza dos Santos, R. Faria-Silva, L. T. da Mata Machado, E. L. Schiffrin, and R. M. Touyz
Angiotensin-(1-7) Through Receptor Mas Mediates Endothelial Nitric Oxide Synthase Activation via Akt-Dependent Pathways
Hypertension,
January 1, 2007;
49(1):
185 - 192.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Canals, L. Jenkins, E. Kellett, and G. Milligan
Up-regulation of the Angiotensin II Type 1 Receptor by the MAS Proto-oncogene Is Due to Constitutive Activation of Gq/G11 by MAS
J. Biol. Chem.,
June 16, 2006;
281(24):
16757 - 16767.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. L. Reudelhuber
A Place in Our Hearts for the Lowly Angiotensin 1-7 Peptide?
Hypertension,
May 1, 2006;
47(5):
811 - 815.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A.S. Santos, C. H. Castro, E. Gava, S. V.B. Pinheiro, A. P. Almeida, R. D. de Paula, J. S. Cruz, A. S. Ramos, K. T. Rosa, M. C. Irigoyen, et al.
Impairment of In Vitro and In Vivo Heart Function in Angiotensin-(1-7) Receptor Mas Knockout Mice
Hypertension,
May 1, 2006;
47(5):
996 - 1002.
[Abstract]
[Full Text]
[PDF]
|
 |
|